GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Core Insights - GeoVax Labs, Inc. is participating in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, where its Chairman & CEO, David Dodd, will discuss innovative therapies for solid tumors [1][2] Company Overview - GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines for infectious diseases and therapies for solid tumor cancers [3] - The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine, which is currently in three Phase 2 clinical trials and has received a BARDA-funded contract for a 10,000-participant Phase 2b clinical trial [3] - In oncology, GeoVax is evaluating Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers [3] - The company holds a strong intellectual property portfolio and worldwide rights for its technologies and products [3]